Professor Tomi P. Mäkelä is Executive Officer of the recently launched iCAN Digital Precision Cancer Medicine Flagship. iCAN is one of six national flagships in Finland 2019-2026 aiming to develop nuclei of scientific excellence into competence clusters for discoveries, innovations, and societal and economic impact. In iCAN a platform joining Precision Cancer Medicine (PCM) with Digital Health is established for discoveries and improved treatments. iCAN is hosted by the University of Helsinki and Helsinki University Hospital HUS and aims for partnerships widely with companies in the pharma/digital health sector.
As Scientific Director of the Finnish Cancer Institute, Mäkelä has been instrumental in establishing the Finnish National Cancer Center FICAN. FCI made the original initiative and Mäkelä has been since on various governmental working groups enabling the establishment of five regional cancer centers in 2018 and the coordinating national center in 2019. He continues to serve on the Ministry of Health FICAN Steering Board as well as on the FICAN South Steering Board as expert member.
Mäkelä is a Professor of Biochemistry and Molecular Biology, and has served as Founding Director of the Helsinki Institute of Life Science HiLIFE, as Director of the Institute of Biotechnology, as Vice Dean for Research of the Faculty of Medicine, and as Director and Dean of the Helsinki Biomedical Graduate School at the University of Helsinki. He is Vice Director of the Center of Excellence in Translational Cancer Biology. Mäkelä acts as panel chair at ERC, and as board member of Biocenter Finland and Finnish Academy of Science and Letters.
Mäkelä is recognised for his work on cell growth signalling and its deregulation in cancer, and especially on the tumour suppressor kinase LKB1 He has 130 publications, 11 100 citations and an H-index of 51. He is an EMBO Member, and has been recognised by the Anders Jahre prize for young investigators.